Home › NDC Lookup › RxCUI directory › RxCUI 205290

Efavirenz 200 MG Oral Capsule — RxCUI 205290

RxNorm drug concept · Semantic clinical drug
RxCUI 205290 Semantic clinical drug · SCD ● Current RxNorm concept 3 FDA products 8 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI205290
Official nameEfavirenz 200 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped3
Package NDCs mapped8
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Efavirenz: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats HIV-1 infection. You take it together with other HIV medicines, never alone. It is used in adults and in children at least 3 months old who weigh at least 3.5 kg.
  • Take it once a day on an empty stomach, ideally at bedtime. Food can raise the drug level and may make side effects worse. Bedtime dosing can make dizziness and similar symptoms ea...
  • Dizziness, vivid dreams, trouble sleeping, headache, nausea, and rash are common. Nervous system symptoms usually start in the first day or two and improve in 2 to 4 weeks. Rash us...
  • Call for severe depression, thoughts of suicide, unusual aggression or paranoia, or a severe rash with blisters, peeling, mouth sores, or fever. Also call for signs of liver troubl...
📖 Read our full Efavirenz guide →

🕸️ Concept Web — How Efavirenz 200 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Efavirenz 200 MG Oral Capsule RxCUI 205290

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Efavirenz 195085
  2. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Efavirenz Oral Capsule 372003
    • Efavirenz Oral Product 1161289
    • Efavirenz Pill 1161290
    • Oral Capsule 316965
    • Oral Product 1151131
    • Pill 1151133
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Efavirenz 200 MG 317359

Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Efavirenz 200 MG SCDC · 317359
  • Efavirenz Oral Capsule SCDF · 372003
  • Efavirenz Oral Product SCDG · 1161289
  • Efavirenz Pill SCDG · 1161290

📦 FDA Products & Package NDCs

3 products · 8 package NDCs
8 package NDCs map to RxCUI 205290 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
65862-0104-10 3 BLISTER PACK in 1 CARTON (65862-104-10) / 10 CAPSULE in 1... Efavirenz Aurobindo Pharma Limited 2017-12-15
65862-0104-30 30 CAPSULE in 1 BOTTLE (65862-104-30) Efavirenz Aurobindo Pharma Limited 2017-12-15
65862-0105-10 3 BLISTER PACK in 1 CARTON (65862-105-10) / 10 CAPSULE in 1... Efavirenz Aurobindo Pharma Limited 2017-12-15
65862-0105-30 30 CAPSULE in 1 BOTTLE (65862-105-30) Efavirenz Aurobindo Pharma Limited 2017-12-15
65862-0106-09 9 BLISTER PACK in 1 CARTON (65862-106-09) / 10 CAPSULE in 1... Efavirenz Aurobindo Pharma Limited 2017-12-15
65862-0106-10 3 BLISTER PACK in 1 CARTON (65862-106-10) / 10 CAPSULE in 1... Efavirenz Aurobindo Pharma Limited 2017-12-15
65862-0106-30 30 CAPSULE in 1 BOTTLE (65862-106-30) Efavirenz Aurobindo Pharma Limited 2017-12-15
65862-0106-90 90 CAPSULE in 1 BOTTLE (65862-106-90) Efavirenz Aurobindo Pharma Limited 2017-12-15
Observed labelers: Aurobindo Pharma Limited (8) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.